Holdings
Ra Capital Management, L.P.
As of Sep 30, 2026, Ra Capital Management, L.P. reported 84 positions worth US$7.11B. Largest: Parabilis Medicines, Inc., Vaxcyte, Inc. and Rhythm Pharmaceuticals, Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Parabilis Medicines, Inc. | 29.2M | US$942M | +245K | Sep 30, 2026 |
| Vaxcyte, Inc. | 11.5M | US$653M | no change | Sep 30, 2026 |
| Rhythm Pharmaceuticals, Inc. | 6.67M | US$635M | no change | Sep 30, 2026 |
| Edgewise Therapeutics, Inc. | 8.39M | US$341M | no change | Sep 30, 2026 |
| Tyra Biosciences, Inc. | 12.2M | US$267M | no change | Sep 30, 2026 |
| Freenome, Inc. | 15.4M | US$242M | new | Sep 30, 2026 |
| Hemab Therapeutics Holdings, Inc. | 7.81M | US$241M | no change | Sep 30, 2026 |
| Septerna, Inc. | 5.5M | US$215M | −1.49M | Sep 30, 2026 |
| SpyGlass Pharma, Inc. | 8.02M | US$209M | no change | Sep 30, 2026 |
| Janux Therapeutics, Inc. | 11.2M | US$193M | no change | Sep 30, 2026 |